$4.81
0.09[1.91%]
At close: Apr 18
$4.81
0[0.00%]
PreMarket: 5:48PM EDT
Syros Pharmaceuticals
(NASDAQ:SYRS)Latest News for Syros Pharmaceuticals Stock (NASDAQ:SYRS)
Syros Pharmaceuticals Stock (NASDAQ: SYRS)
Categories: All
Tuesday, April 09, 2024
- Crude Oil Down Over 1%; Cognyte Software Shares PlummetAvi Kapoor - Apr 9, 2024, 2:34PM
- Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Apr 9, 2024, 1:12PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Apr 9, 2024, 12:31PM
- Syros Receives Fast Track Designation From The FDA For Tamibarotene For The Treatment Of Newly Diagnosed Unfit AML With RARA Gene OverexpressionBenzinga Newsdesk - Apr 9, 2024, 7:10AM
Wednesday, April 03, 2024
Tuesday, April 02, 2024
Monday, April 01, 2024
Wednesday, March 27, 2024
Tuesday, March 26, 2024
Monday, March 25, 2024
Monday, March 11, 2024
Monday, February 12, 2024
Monday, January 29, 2024
Tuesday, January 09, 2024
Monday, January 08, 2024
Monday, January 01, 2024
Tuesday, December 19, 2023
- 12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga Insights - Dec 19, 2023, 4:31PM
- Syros Pharmaceuticals shares are trading higher. The company announced the pricing of a $45 million underwritten offering of 4,939,591 shares at $4.42 per share.Benzinga Newsdesk - Dec 19, 2023, 1:27PM
- Syros Pharmaceuticals Has Priced An Underwritten Offering Of 4.9M Shares At $4.42/Share, And Pre-funded Warrants To Purchase 5,242,588 Shares At $4.419 Per Pre-funded Warrant, With Gross Proceeds Of Approximately $45MBenzinga Newsdesk - Dec 19, 2023, 7:36AM
Wednesday, December 06, 2023
- Why Is Blood Cancer Focused Syros Pharmaceuticals Stock Soaring Today?Vandana Singh - Dec 6, 2023, 12:55PM
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga Insights - Dec 6, 2023, 12:31PM
- Syros Pharmaceuticals Announced Initial Data From Its Ongoing SELECT-AML-1 Phase 2 Trial Of Tamibarotene In Combination With Venetoclax And Azacitidine In Newly Diagnosed Patients With Acute Myeloid Leukemia And Rara Gene OverexpressionBenzinga Newsdesk - Dec 6, 2023, 7:10AM
Tuesday, November 14, 2023
- Earnings Scheduled For November 14, 2023Benzinga Insights - Nov 14, 2023, 8:23AM
- Syros' Cash, Cash Equivalents And Marketable Securities Of $112M Is Expected To Be Sufficient To Fund Its Anticipated Operating Expenses And Capital Expenditure Requirements Into 2025Benzinga Newsdesk - Nov 14, 2023, 7:40AM
- Syros Pharmaceuticals Q3 EPS $(1.43) May Not Be Comparable To $(1.14) Estimate, Sales $3.76M Miss $3.94M EstimateBenzinga Newsdesk - Nov 14, 2023, 7:02AM
Monday, November 13, 2023
Friday, October 20, 2023
Tuesday, October 03, 2023
Monday, October 02, 2023
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Oct 2, 2023, 1:30PM
- Syros Announces Planned Workforce Reduction Of ~35% Sharpens Focus Of Organization On Late-Stage Development Of Tamibarotene In MDS And AML And Ongoing Pre-Launch ActivitiesBenzinga Newsdesk - Oct 2, 2023, 8:49AM
- Syros Announces Planned CEO Leadership Transition And Strategic Reorganization To Support Long-Term Business Growth And Maturation Into A Commercial Biopharmaceutical Co; Conley Chee, CCO And CBO, To succeed Nancy Simonian, M.D. As CEO; Effective Dec 1Benzinga Newsdesk - Oct 2, 2023, 8:49AM
Friday, August 11, 2023
Wednesday, August 09, 2023
Tuesday, August 08, 2023
Monday, August 07, 2023
Monday, July 24, 2023
- Pfizer To Terminate Development Pact With Syros Pharmaceuticals For Novel Therapies For Two Blood DisordersVandana Singh - Jul 24, 2023, 8:48AM
- Friday, Syros Pharmaceuticals Received Notice From Pfizer, As Successor To Global Blood Therapeutics, Exercising Its Right To Terminate An Agreement Dated December 17, 2019 Related To Sickle Cell Disease And Beta-thalassemia TherapiesBenzinga Newsdesk - Jul 24, 2023, 5:20AM
Thursday, May 11, 2023
Wednesday, May 10, 2023
- Earnings Scheduled For May 10, 2023Benzinga Insights - May 10, 2023, 9:12AM
- Syros Pharmaceuticals: Q1 Earnings InsightsBenzinga Insights - May 10, 2023, 7:40AM
- Syros Pharmaceuticals' Cash Balance Of $166M Will Be Sufficient To Fund Its Anticipated Operating Expenses And Capital Expenditure Requirements Into 2025Benzinga Newsdesk - May 10, 2023, 7:34AM
- Syros Pharmaceuticals Q1 EPS $(0.85) Beats $(1.09) Estimate, Sales $2.95M Miss $3.26M EstimateBenzinga Newsdesk - May 10, 2023, 7:33AM